News from abbvie A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

13:45 ET AbbVie Declares Quarterly Dividend

The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $1.07 per share. The cash dividend is payable August 15,...


Jun 12, 2019, 18:00 ET New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks Presented at EULAR

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results from the Phase 3 clinical trials SELECT-EARLY and ...


Jun 11, 2019, 07:00 ET New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results showing a significant number of patients treated...


Jun 10, 2019, 12:26 ET AbbVie Employees to Help Underserved Communities in Sixth-Annual "Week of Possibilities"

AbbVie, a research-based global biopharmaceutical company, kicks off its sixth annual Week of Possibilities global employee volunteering program this ...


Jun 07, 2019, 08:00 ET AbbVie to Present at the Goldman Sachs Global Healthcare Conference

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 40th Annual Global Healthcare...


Jun 04, 2019, 11:09 ET AbbVie Presents Data from Venetoclax Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia

- Phase 3 data from CLL14 study were highlighted in an oral presentation (abstract #7502) today at ASCO and published in the New England Journal of...


May 30, 2019, 08:45 ET AbbVie Presents Results from Several Studies and Clinical Trials Investigating Medicines Across More than 15 Cancers at the 2019 ASCO and EHA Meetings

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present more than 40 data updates across its oncology ...


May 17, 2019, 08:45 ET AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the Phase 3 INTELLANCE-1 study of depatuxizumab mafodotin...


May 15, 2019, 14:19 ET AbbVie Announces US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ...


May 14, 2019, 08:34 ET AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim

AbbVie (NYSE: ABBV) announced that it has resolved U.S. HUMIRA (adalimumab) litigation with Boehringer Ingelheim (BI). Under the terms of the...


May 14, 2019, 08:00 ET AbbVie to Present at the UBS Global Healthcare Conference

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the UBS Global Healthcare Conference on Tuesday, May 21,...


May 07, 2019, 08:00 ET AbbVie to Present at the Bank of America Merrill Lynch Healthcare Conference

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Bank of America Merrill Lynch Healthcare Conference...


Apr 30, 2019, 10:47 ET AbbVie apresenta Resultados Financeiros do primeiro trimestre de 2019

A AbbVie (NYSE:ABBV), companhia biofarmacêutica global, anunciou os resultados financeiros do T1 2019, encerrado em 31 de março de 2019. O anúncio...


Apr 30, 2019, 07:45 ET European Commission Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Commission (EC) has approved SKYRIZI™...


Apr 30, 2019, 07:08 ET AbbVie to Present New and Updated Data of Investigational Medicines for Parkinson's Disease and Multiple Sclerosis at 2019 American Academy of Neurology Annual Meeting

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced experts in the neuroscience field will present six abstracts, ...


Apr 25, 2019, 07:42 ET AbbVie Reports First-Quarter 2019 Financial Results

AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2019. "We are off to another excellent start, including first...


Apr 23, 2019, 18:19 ET AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI™ (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved...


Apr 17, 2019, 11:00 ET AbbVie Announces Call for Entries for the AbbVie CF Scholarship for the 2019-2020 Academic School Year

AbbVie, a global research and development-based biopharmaceutical company, today announced that the AbbVie CF Scholarship program is now accepting...


Apr 03, 2019, 08:00 ET AbbVie to Host First-Quarter 2019 Earnings Conference Call

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its first-quarter 2019 financial results on Thursday, April 25...


Mar 26, 2019, 01:00 ET AbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and Welfare...


Mar 21, 2019, 14:59 ET AbbVie Donates $40 Million to Rebuild North Chicago Middle School

AbbVie, a research-based global biopharmaceutical company, today announced a donation of $40 million to North Chicago Community Unit School District...


Mar 19, 2019, 08:45 ET AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has placed a...


Mar 07, 2019, 08:46 ET AbbVie Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment in Previously-Untreated Chronic Lymphocytic Leukemia Patients

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted a...


Mar 01, 2019, 08:00 ET AbbVie to Present at the Barclays Global Healthcare Conference

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Barclays Global Healthcare Conference on Wednesday,...


Mar 01, 2019, 07:00 ET AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI™) for the Treatment of Moderate to Severe Plaque Psoriasis

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Medicines Agency's (EMA) Committee for...